Cencora Raises Annual Profit Forecast Above Estimates Despite Q2 Revenue Miss
COR is trading near its 52-week low of $271 (6.3% above the low).
Summary
Cencora (COR) reported second-quarter results that missed Wall Street estimates for both revenue ($78.4 billion vs $81.09 billion expected) and adjusted EPS ($4.75 vs $4.81 expected). Despite this, the company significantly raised its full-year profit forecast to $17.65-$17.90 per share, exceeding its previous guidance and analyst expectations of $17.60 per share. This positive outlook is attributed to robust demand for high-margin specialty medicines and GLP-1 drugs, alongside strategic divestitures and acquisitions aimed at strengthening its core drug distribution business. While the quarterly miss is a minor negative, the raised annual guidance provides a strong forward-looking positive signal for the company's profitability, indicating management's confidence in future performance. Peer Cardinal Health (CAH) also recently raised its profit forecast despite a revenue miss.
At the time of this announcement, COR was trading at $288.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $59.5B. The 52-week trading range was $271.00 to $377.54. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.